3O: Phase I/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts
2025 · Journal of Thoracic Oncology · 5 citations
https://doi.org/10.1016/s1556-0864(25)00198-4
A
A. Prelaj
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
6
Citations
1
h-index
0
i10-index
A. Prelaj is an academic researcher from Fondazione IRCCS Istituto Nazionale dei Tumori. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research. The author has an h-index of 1, co-authored 9 publications.
Papers by this author
worksLBA75 Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study
2025 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2025.09.089
OA09.02 I3LUNG-PDSS: A Multimodal AI-Based Clinical Decision Support System for Predicting Immunotherapy Efficacy in Metastatic NSCLC
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.09.059
P1.11.66 Cost-Effective Machine Learning for Predicting Survival in NSCLC Patients on Immunotherapy: Insights From the APOLLO11 Study
2025 · Journal of Thoracic Oncology · 0 citations
https://doi.org/10.1016/j.jtho.2025.09.366
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat